Earnings set 24 Mar: Transgene (TNG.PA) EURONEXT €0.75 intraday, catalyst preview

The next earnings release is the immediate risk for TNG.PA stock: Transgene SA (TNG.PA) trades €0.75 intraday on EURONEXT on 19 Mar 2026, down 2.58% today on volume 75,391. Investors will focus on cash runway, R&D spend and clinical updates ahead of results due 24 Mar 2026. Meyka AI’s real-time signals highlight a below-average liquidity profile and a binary biotech risk tied to trial readouts and partner milestones.

TNG.PA stock: Intraday snapshot and market context

Transgene SA (TNG.PA) is trading €0.75 intraday with a day range of €0.75–€0.76 and market cap €101,688,504. Volume today is 75,391, below the 30‑day average of 105,462, and relative volume is 0.33. The 50‑day average price is €0.87 and the 200‑day average is €1.01, showing a short-term downtrend versus longer-term levels.

TNG.PA stock: Earnings preview and what to watch

Earnings are scheduled for 24 Mar 2026 and will act as the next catalyst for TNG.PA stock. Key items to monitor are cash burn, R&D expense cadence, and any clinical updates on TG4050, TG6002 and TG4001. Management commentary on partnerships with AstraZeneca, Merck KGaA and Pfizer could affect sentiment. For balance sheet details, see the company filings and public financials source.

TNG.PA stock: Financials, valuation and profitability metrics

Transgene posts EPS -0.28 and a trailing PE of -2.75, reflecting ongoing losses tied to R&D. Price-to-sales is 32.89, cash per share is €0.13, and revenue per share TTM is €0.02. The current ratio is 0.54, signalling a tight short‑term liquidity position. Net income margin is -11.90% and research intensity remains high at R&D-to-revenue 11.43x. These metrics show a capital-intensive biotech still funding trials rather than generating commercial revenue.

TNG.PA stock: Technicals and trading signals ahead of earnings

Technically, TNG.PA shows RSI 37.14, MACD histogram -0.01 and ADX 35.31, indicating a strong directional trend lower. Bollinger Bands are 0.74–0.91 with ATR €0.03, implying typical intraday swings near 4% of the current price. Watch for an increase in OBV and volume ahead of earnings; a spike can magnify moves given the low free float and average turnover.

Meyka AI rates and TNG.PA stock forecast

Meyka AI rates TNG.PA with a score out of 100: 67.21 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects monthly €0.73, quarterly €1.05, and yearly €1.15 targets. Compared with the current price €0.754, the yearly projection implies an upside of 52.95%. Forecasts are model‑based projections and not guarantees.

TNG.PA stock: Price targets and scenarios

We outline scenario targets to frame risk: a conservative downside target €0.60 (implied -20.37%), a base case near the Meyka yearly forecast €1.15 (implied +52.95%), and a long‑term upside case ~€1.93 (5‑year model, implied +156.46%). These scenarios assume binary trial outcomes, partner milestone receipts, or dilution events. Use these targets to size risk for earnings volatility.

Final Thoughts

TNG.PA stock is entering earnings season with a narrow cash buffer, heavy R&D spending and significant trial milestones that can move the stock sharply. Meyka AI’s model projects a yearly level of €1.15, implying +52.95% versus the current €0.754, but outcomes hinge on clinical news and any guidance on cash runway. Technical indicators show the stock is oversold to neutral and volume must pick up to validate any reversal. Risk factors include further dilution, trial delays or weak partner commentary; upside requires positive data or milestone payments. For active traders, expect higher intraday ATR and wider spreads around 24 Mar 2026. Investors seeking exposure should weigh biotech binary risk, Transgene’s negative margins and current ratio 0.54 against the potential reward outlined in the model. Forecasts are model‑based projections and not guarantees, and Meyka AI provides this as data-driven market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.